Volume 16, Issue 4 (April 2018)
IJRM 2018, 16(4): 267-274 |
Back to browse issues page
1- Department of Biology, Faculty of Science, Arak University, Arak, Iran
2- Department of Biology, Faculty of Science, Arak University, Arak, Iran , m-Soleimani@araku.ac.ir
3- Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran
2- Department of Biology, Faculty of Science, Arak University, Arak, Iran , m-Soleimani@araku.ac.ir
3- Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran
Abstract: (3793 Views)
Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder featured by insulin resistance and hyperandrogenism. Testosterone enanthate can induce PCOS in mice models.
Objective: We investigated the ovary stereological features along with the oxidative stress and inflammatory factors in mice following PCOS induction using testosterone enanthate.
Materials and Methods: Twelve female NMRI mice (3 wk old) were divided into 2 groups (n=6/each): Control and PCOS. PCOS was induced through daily injections of testosterone enanthate (1 mg/100g subcutaneous s.c for 5 wk). Finally, ovaries were studied stereologically. The serum levels of the follicle-stimulating hormone, luteinizing hormone, testosterone, interleukin-6, and tumor necrosis factor-α were measured using ELISA kit. Serum levels of Malondialdehyde and the antioxidant capacity were measured relatively using thiobarbituric acid and ferric reducing antioxidant power assay.
Results: The mean total volume of ovary and the mean volume of cortex (p<0.001), volume of oocyte in the preantral (p=0.011) and antral follicle (p=0.015), thickness of zona pellucida (p=0.016), the number of antral follicles (p=0.012), the serum levels of follicle-stimulating hormone (p<0.001) and the antioxidant capacity (p=0.020) reduced significantly in the PCOS group compared to the control. The number of primary (p=0.017) and preantral (p=0.006) follicles and the serum levels of testosterone (p<0.001), Luteinizing hormone (p=0.002), Malondialdehyde, Interleukin 6 and Tumor necrosis factor-α (p<0.001) showed a significant increase in the PCOS group compared to the control.
Conclusion: Testosterone enanthate induced PCOS causes stereological features in the ovary, increases the oxidative stress and inflammatory markers in mice.
Objective: We investigated the ovary stereological features along with the oxidative stress and inflammatory factors in mice following PCOS induction using testosterone enanthate.
Materials and Methods: Twelve female NMRI mice (3 wk old) were divided into 2 groups (n=6/each): Control and PCOS. PCOS was induced through daily injections of testosterone enanthate (1 mg/100g subcutaneous s.c for 5 wk). Finally, ovaries were studied stereologically. The serum levels of the follicle-stimulating hormone, luteinizing hormone, testosterone, interleukin-6, and tumor necrosis factor-α were measured using ELISA kit. Serum levels of Malondialdehyde and the antioxidant capacity were measured relatively using thiobarbituric acid and ferric reducing antioxidant power assay.
Results: The mean total volume of ovary and the mean volume of cortex (p<0.001), volume of oocyte in the preantral (p=0.011) and antral follicle (p=0.015), thickness of zona pellucida (p=0.016), the number of antral follicles (p=0.012), the serum levels of follicle-stimulating hormone (p<0.001) and the antioxidant capacity (p=0.020) reduced significantly in the PCOS group compared to the control. The number of primary (p=0.017) and preantral (p=0.006) follicles and the serum levels of testosterone (p<0.001), Luteinizing hormone (p=0.002), Malondialdehyde, Interleukin 6 and Tumor necrosis factor-α (p<0.001) showed a significant increase in the PCOS group compared to the control.
Conclusion: Testosterone enanthate induced PCOS causes stereological features in the ovary, increases the oxidative stress and inflammatory markers in mice.
Type of Study: Original Article |
Subject:
Reproductive Biology
References
1. Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertil Soc J 2011; 16: 19-37. [DOI:10.1016/j.mefs.2010.10.002]
2. Ali HI, Elsadawy ME, Khater NH. Ultrasound assessment of polycystic ovaries: Ovarian volume and morphology; which is more accurate in making the diagnosis?! Egypt J Radiol Nuclear Med 2016; 47: 347-350. [DOI:10.1016/j.ejrnm.2015.10.002]
3. Velez LM, Heber MF, Ferreira SR, Abruzzese GA, Reynoso RM, Motta AB. Effect of hyperandrogenism on ovarian function. Reproduction 2015; 149: 577-585. [DOI:10.1530/REP-15-0041]
4. Beloosesky R, Gold R, Almog B, Sasson R, Dantes A, land-Bracha A, et al. Induction of polycystic ovary by testosterone in immature female rate: Modulation of apoptosis and attenuation of glucose/insulin ratio. Int J Mol Med 2004; 14: 207-215.
5. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 2003; 101: 1177-1182.
6. Murri M, Luque-Ramı’rez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 2013; 19, 268-288. [DOI:10.1093/humupd/dms059]
7. Xiong YL, Liang XY, Yang X, Li Y, Wei LN. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 159: 148-150. [DOI:10.1016/j.ejogrb.2011.07.012]
8. Urman B, Tiras B, Yakin K. Assisted reproduction in the treatment of polycystic ovarian syndrome. Reprod Biomed Online 2004; 8: 419-430. [DOI:10.1016/S1472-6483(10)60926-1]
9. Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update 2011; 17: 17-33. [DOI:10.1093/humupd/dmq032]
10. Franks S. Do animal models of polycystic ovary syndrome help to understand its pathogenesis and management? Yes, but their limitations should be recognized. Endocrinology 2009; 150: 3983-3985. [DOI:10.1210/en.2009-0652]
11. Smith P, Steckler TL, Veiga-Lopez A, Padmanabhan V. Developmental programming: differential effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, depletion of follicular reserve, and ovarian morphology in sheep. Biol Reprod 2009; 80: 726-736. [DOI:10.1095/biolreprod.108.072801]
12. Abbott DH, Nicol LE, Levine JE, Xu N, Goodarzi MO, Dumesic DA. Nonhuman primate models of polycystic ovary syndrome. Mol Cell Endocrinol 2013; 373: 21-28. [DOI:10.1016/j.mce.2013.01.013]
13. Dumesic DA, Abbott DH, Eisner JR, Goy RW. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril 1997; 67: 155-163. [DOI:10.1016/S0015-0282(97)81873-0]
14. Caldwell AS, Middleton LJ, Jimenez M, Desai R, McMahon AC, Allan CM, et al. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models. Endocrinology 2014; 155: 3146-3159. [DOI:10.1210/en.2014-1196]
15. Skrtic A, Sokolic L, Borovecki A, Rosa J, Fenzl V. Immunohistochemical localization of CD31, NOTCH1 and JAGGED1 proteins in experimentally induced polycystic ovaries of immature rats. Acta Histochem 2011; 113: 262-269. [DOI:10.1016/j.acthis.2009.10.008]
16. Mahmoodi M, Soleimani Mehranjani M, Shariatzadeh SM, Eimani H, Shahverdi, A. Effects of erythropoietin on ischemia, follicular survival, and ovarian function in ovarian grafts. Reproduction 2014; 147: 733-741. [DOI:10.1530/REP-13-0379]
17. Myers M, Britt, KL, Wreford NG, Ebling FJ Kerr JB. Methods for quantifying follicular numbers within the mouse ovary. Reproduction 2004; 127: 569-580. [DOI:10.1530/rep.1.00095]
18. Calado AM, Rocha E, Colaco A, Sousa M. Stereological characterization of bovine (Bos taurus) cumulus-oocyte complexes aspirated from small antral follicles during the metestrus and proestrus phases. Theriogenology 2003; 60: 429-443. [DOI:10.1016/S0093-691X(03)00038-4]
19. Ferrando RE, Nyengaard JR, Hays SR, Fahy JV, Woodruff PG. Applying stereology to measure thickness of the basement membrane zone in bronchial biopsy specimens. J Allergy Clin Immunol 2003; 112: 1243-1245. [DOI:10.1016/j.jaci.2003.09.038]
20. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302-310. [DOI:10.1016/S0076-6879(78)52032-6]
21. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power" the FRAP assay. Ana Biochem 1996; 239: 70-76. [DOI:10.1006/abio.1996.0292]
22. Hubscher CH, Brooks DL, Johnson JR. A quantitative method for assessing stages of the rat estrous cycle. Biotech Histochem 2005; 80: 79-87. [DOI:10.1080/10520290500138422]
23. Qiu S, Wu C, Lin F, Chen L, Huang Z, Jiang Z. Exercise training improved insulin sensitivity and ovarian morphology in rats with polycystic ovary syndrome. Horm Metab Res 2009; 41: 880-885. [DOI:10.1055/s-0029-1234119]
24. Zhai HL, Wu H, Xu H, Weng P, Xia FZ, Chen Y, et al. Trace glucose and lipid metabolism in high androgen and high-fat diet induced polycystic ovary syndrome rats. Reprod Biol Endocrinol 2012; 10: 1-9. [DOI:10.1186/1477-7827-10-5]
25. Ikeda K, Baba T, Morishita M, Honnma H, Endo T, Kiya T, et al. Long-term treatment with dehydroepiandrosterone may lead to follicular atresia through interaction with anti-mullerian hormone. J Ovarian Res 2014; 7: 1-8. [DOI:10.1186/1757-2215-7-46]
26. Rezvanfar MA, Shojaei Saadi HA, Gooshe M, Abdolghaffari AH, Baeeri M, Abdollahi M. Ovarian aging like phenotype in the hyperandrogenism-induced murine model of polycystic ovary. Oxid Med Cell Longev 2014; 2014: 1-10. [DOI:10.1155/2014/948951]
27. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Exp Rev Mol Med 2008; 10: 1-21. [DOI:10.1017/S1462399408000598]
28. Noorafshan A, Ahmadi M, Mesbah SF, Karbalay-Doust S. Stereological study of the effects of letrozole and estradiol valerate treatment on the ovary of rats. Clin Exp Reprod Med 2013; 40: 115-121. [DOI:10.5653/cerm.2013.40.3.115]
29. Marquard KL, Stephens SM, Jungheim ES, Ratts VS, Odem RR, Lanzendorf S, et al. Polycystic ovary syndrome and maternal obesity affect oocyte size in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2011; 95: 2146-2149. [DOI:10.1016/j.fertnstert.2010.10.026]
30. Ouladsahebmadarek E, Khaki A. [Ultra-structural Study by Transmission Electron Microscopy: Effect of Omega-3 on Ovary Cell Organelles after Experimental Induced Poly Cystic Ovary Syndrome]. Int J Women's Health Reprod Sci 2014; 2: 186-194. (in Persian) [DOI:10.15296/ijwhr.2014.27]
31. Wassarman PM, Litscher ES. Influence of the zona pellucida of the mouse egg on folliculogenesis and fertility. Int J Dev Biol 2012; 56: 833-839. [DOI:10.1387/ijdb.120136pw]
32. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, et al. Polycystic ovary syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000; 85: 4047-4052.
33. Pushpa N, Kalavathy S. Effect of mehani on hormonal profile in wistar rats induced with polycystic ovary syndrome. Biology 2013; 1: 21-24.
34. Gonza´lez F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012; 77: 300-305. [DOI:10.1016/j.steroids.2011.12.003]
35. Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-α stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod 1999; 61: 993-998. [DOI:10.1095/biolreprod61.4.993]
36. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21: 1426-1432. [DOI:10.1093/humrep/del003]
37. Dhindsa G, Bhatia R, Dhindsa M, Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 2004; 50: 140-144.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |